West Tower Group’s DexCom DXCM Stock Holding History

West Tower Group’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-45	Closed	-$5.78K	–	658
2023 Q2	$5.78K	Buy	+45	New	+$5.44K	﹤0.01%	498

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

West Tower Group's DXCM Position: Q3 2023 in Review

West Tower Group sold out of DexCom (DXCM) in Q3 2023, closing a stake of 45 shares — an estimated $5.78K sold.

West Tower Group first reported a position in DXCM in Q2 2023 and held it in 1 quarter. The position peaked at $5.78K in Q2 2023. 903 funds tracked by Wall St. Rank hold DXCM as of Q3 2023.

West Tower Group reported no remaining DexCom position as of Q3 2023 after selling out during the quarter.
West Tower Group sold 45 DexCom shares in Q3 2023, an estimated $5.78K.
West Tower Group first reported a position in DexCom in Q2 2023 and held it in 1 quarter.
West Tower Group's DexCom position peaked at $5.78K in Q2 2023.
903 funds tracked by Wall St. Rank held DexCom as of Q3 2023.

Based on West Tower Group's 13F filing for Q3 2023, filed 14 Nov 2023.